Trident Texofab Q1FY27 net profit rises 49% to ₹52.18 lakh on cost control
Trident Texofab’s Q1FY27 results show a return to profitability with a net profit of ₹52.18 lakh, contrasting with a ₹200.94 lakh loss in Q1FY25. This improvement occurred despite a decline in revenue from operations to ₹2,614.26 lakh, primarily due to a sharp decrease in material costs. Additionally, the company announced the resignation of its statutory auditor, Shah Kailash & Associates LLP, effective August 10, 2026, citing professional commitments, and appointed M/s. Prit Agrawal & Co. as the new internal auditor for FY27.
*this image is generated using AI for illustrative purposes only.
Trident Texofab reported a net profit of ₹52.18 lakh for the quarter ended June 30, 2026, marking a sharp recovery from the ₹200.94 lakh loss recorded in the same period last year. Revenue from operations declined to ₹2,614.26 lakh from ₹2,807.68 lakh in Q1FY25, yet the company achieved profitability driven by lower material costs and improved operational efficiency. The turnaround is significant for shareholders as it ends a streak of losses in the preceding quarter, demonstrating effective cost management despite a dip in sales volume.
The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors in a meeting held on August 10, 2026. The results were reviewed by the Statutory Auditor, Shah Kailash & Associates LLP (FRN: 109647W), under Standard on Review Engagement (SRE) 2410. The disclosure was made pursuant to Regulation 33 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An extract of the financial results will be published in newspapers and made available on the company’s website.
Financial Performance
The company’s total income stood at ₹2,632.79 lakh, down from ₹2,851.58 lakh in Q1FY25. Despite the revenue dip, total expenses decreased significantly to ₹2,564.07 lakh from ₹2,714.67 lakh in the prior year quarter. This cost discipline resulted in a profit before tax of ₹68.72 lakh, compared to ₹136.92 lakh in Q1FY25. After accounting for a total tax expense of ₹16.54 lakh, the net profit for the period was ₹52.18 lakh. Earnings per share (basic) were ₹0.35, up from ₹0.72 in the previous year but a stark improvement from the loss of ₹1.30 per share in Q4FY25.
| Particulars | Q1 FY26 (₹ Lakh) | Q4 FY25 (₹ Lakh) | Q1 FY25 (₹ Lakh) |
|---|---|---|---|
| Revenue From Operations | 2,614.26 | 3,357.02 | 2,807.68 |
| Other Income | 18.53 | 53.23 | 43.91 |
| Total Income | 2,632.79 | 3,410.25 | 2,851.58 |
| Total Expenses | 2,564.07 | 3,541.00 | 2,714.67 |
| Profit Before Tax | 68.72 | -233.41 | 136.92 |
| Net Profit/Loss | 52.18 | -200.94 | 101.59 |
| EPS (Basic) | 0.35 | -1.30 | 0.72 |
Auditor Resignation and Appointment
Shah Kailash & Associates LLP resigned as Statutory Auditor with effect from August 10, 2026. In their resignation letter, the firm stated that increasing professional commitments and workload made it difficult to devote requisite time and resources to the role. They confirmed there were no disagreements with management regarding accounting policies or auditing procedures. The firm had been appointed at the 16th Annual General Meeting on September 27, 2024, for a four-year term ending in FY28. The resignation was disclosed under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Concurrently, the Board appointed M/s. Prit Agrawal & Co. (FRN: 152249W) as the Internal Auditor for the financial year 2026-27. The firm, based in Ahmedabad, provides services including direct and indirect taxation, statutory audit, and business advisory. This appointment was also disclosed pursuant to Regulation 30 of the SEBI Listing Regulations.
What the Numbers Show
The divergence between revenue decline and profit improvement highlights a structural shift in cost management. While revenue from operations fell by approximately 6.9% year-on-year, total expenses dropped by roughly 5.5%. More critically, the cost of materials consumed plummeted from ₹647.39 lakh in Q1FY25 to ₹233.29 lakh in Q1FY26, a reduction of over 64%. This suggests either a change in product mix towards lower-cost items or significant efficiencies in procurement. However, purchases of stock-in-trade rose sharply to ₹2,028.42 lakh from ₹1,798.39 lakh, indicating increased inventory buildup despite lower sales volume. Investors should monitor whether this inventory accumulation aligns with future demand expectations or signals potential working capital pressure.
Historical Stock Returns for Trident Texofab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.32% | -12.73% | -33.51% | -84.91% | -89.77% | -36.69% |
Will the sharp 64% reduction in material costs be sustainable in Q2, or does it indicate a temporary shift to lower-margin product mixes?
How will the significant increase in stock-in-trade purchases impact Trident Texofab's working capital efficiency and cash flow in the coming quarters?
What is the timeline for appointing a new Statutory Auditor following Shah Kailash & Associates' resignation, and could this transition delay future financial disclosures?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
